CP and COVID-19: The central hypothesis of this trial was that in patients with severe COVID-19, treatment with CP would be associated with a reduction of viral load and an increase in antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at 28 days.